Searched for
BIOSIMILAR CANCER DRUG
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosis- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analysts
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral post
- Sun Pharma sees steady FY27 growth, progresses $11.75 bn Organon integration dealSun Pharma anticipates strong growth in the coming years. The company expects a high single-digit increase in its overall sales by FY2027. ...23 May, 2026, 01.04 AM IST
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...10 May, 2026, 08.50 AM IST
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...05 May, 2026, 05.35 PM IST
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...05 May, 2026, 01.56 PM IST
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...05 May, 2026, 11.51 AM IST
- Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilarAurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...01 May, 2026, 02.53 PM IST
- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...27 Apr, 2026, 10.33 AM IST
- US FDA accepts Biocon's cancer drug application for reviewBiocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for ...09 Mar, 2020, 10.13 AM IST
- Intas launches biosimilar Bevacizumab with aggressive pricingBiosimilar drugs are the follow on versions of biologic drugs which are composed of sugars, proteins, nucleic acids or complex combinations...04 Oct, 2017, 08.40 PM IST
- Big boost for Biocon as USFDA Onco committee approves company's first breast cancer biosimilar drugThe USFDA's Oncology Drugs Advisory Committee voted 16-0 in support of the eligible indications of the original product.14 Jul, 2017, 08.38 AM IST
- Delhi High Court gives Biocon, Mylan green light to market blockbuster biosimilar for three cancersThe court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...04 Mar, 2017, 11.42 AM IST
- US FDA accepts Biocon-Mylan biosimilar application for proposed anti-cancer bio-similarBiocon said that the FDA's acceptance for review of this biosimilar is an outcome of the company’s strong R&D and manufacturing capabilitie...16 Feb, 2017, 08.28 PM IST
- Biosimilar drugs are priced too high and do little to improve accessibility: DoctorsBiosimilar drugs are follow-on biologics that have nearly the same efficacy as the original drug and used to treat cancer or autoimmune dis...01 Jul, 2016, 03.57 AM IST
- Government set to release revised biosimilar guidelines in July 2016The ministry expects the final guidelines to uphold the safety and efficacy of biosimilar drugs hitting the Indian market through stringent...17 Jun, 2016, 09.34 PM IST
- Delhi High Court asks Roche to explain lawsuit over Avastin copyRoche, which invented the drug and markets it under the blockbuster brand ‘Avastin’, has argued that Hetero’s drug is not a biosimilar to b...24 May, 2016, 09.39 PM IST
- Roche’s reputation at stake if Avastin biosimilar approved without trial: Kapil SibalThe judge asked the company to submit a compilation of judgments highlighting the protection given to drug innovators to support its call.21 May, 2016, 01.14 PM IST
- Intas Pharmaceutical launches low cost drug 'Mabtas' for cancer treatmentIntas Pharmaceutical today said it has launched 'Mabtas' a new low cost drug for treating cancer in India.30 Apr, 2013, 06.54 PM IST
Load More
